AU1877700A - Treatment of conditions with a need for the inhibition of gsk-3 - Google Patents

Treatment of conditions with a need for the inhibition of gsk-3

Info

Publication number
AU1877700A
AU1877700A AU18777/00A AU1877700A AU1877700A AU 1877700 A AU1877700 A AU 1877700A AU 18777/00 A AU18777/00 A AU 18777/00A AU 1877700 A AU1877700 A AU 1877700A AU 1877700 A AU1877700 A AU 1877700A
Authority
AU
Australia
Prior art keywords
gsk
inhibition
treatment
conditions
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18777/00A
Inventor
Matthew Paul Coghlan
Julie Caroline Holder
Alastair David Reith
David Glynn Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU1877700A publication Critical patent/AU1877700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU18777/00A 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3 Abandoned AU1877700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828640.4A GB9828640D0 (en) 1998-12-23 1998-12-23 Novel method and compounds
GB9828640 1998-12-23
PCT/GB1999/004374 WO2000038675A1 (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3

Publications (1)

Publication Number Publication Date
AU1877700A true AU1877700A (en) 2000-07-31

Family

ID=10845024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18777/00A Abandoned AU1877700A (en) 1998-12-23 1999-12-22 Treatment of conditions with a need for the inhibition of gsk-3

Country Status (4)

Country Link
EP (1) EP1140070A1 (en)
AU (1) AU1877700A (en)
GB (1) GB9828640D0 (en)
WO (1) WO2000038675A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res Drugs inhibiting cell death
AU2337601A (en) * 1999-12-23 2001-07-09 Ontario Cancer Institute, The Inhibition of gsk-3beta
HUP0302002A3 (en) 2000-05-11 2007-02-28 Consejo Superior Investigacion Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them
ES2166328B1 (en) * 2000-05-11 2003-09-16 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES
CZ2003555A3 (en) 2000-07-27 2004-03-17 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
EP1698627A1 (en) 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PL366009A1 (en) * 2000-10-02 2005-01-24 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
NZ535616A (en) * 2000-11-07 2006-03-31 Novartis Ag Indolymaleimide derivatives as protein kinase c inhibitors
MXPA03005139A (en) 2000-12-08 2004-01-29 Ortho Mcneil Pharm Inc Macroheterocylic compounds useful as kinase inhibitors.
KR100909665B1 (en) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
AU2002259071A1 (en) 2001-04-30 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
WO2003024447A1 (en) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
EP2198867A1 (en) 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
AU2003235798A1 (en) * 2002-01-10 2003-07-24 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
RU2004126671A (en) 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) HETEROARYL COMPOUNDS USEFUL AS GSK-3 INHIBITORS
US20050203059A1 (en) * 2002-03-01 2005-09-15 Harrison Stephen D. Methods and compositions for treatment of ischemia
ATE346070T1 (en) 2002-03-05 2006-12-15 Lilly Co Eli PURINE DERIVATIVES AS KINASE INHIBITORS
KR20040091113A (en) * 2002-03-08 2004-10-27 일라이 릴리 앤드 캄파니 Pyrrole-2,5-dione derivatives and their use as gsk-3 inhibitors
ATE387444T1 (en) 2002-05-08 2008-03-15 Janssen Pharmaceutica Nv SUBSTITUTED PYRROLINES AS KINASE INHIBITORS
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003254051A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
NZ538426A (en) 2002-08-02 2007-05-31 Vertex Pharma Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3)
JP4817661B2 (en) 2002-12-18 2011-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド Triazolopyridazine as a protein kinase inhibitor
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
JP2006521386A (en) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Substituted pyrroline, a kinase inhibitor
JPWO2004091663A1 (en) * 2003-04-18 2006-07-06 協和醗酵工業株式会社 Nerve regeneration drug
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
WO2005086814A2 (en) * 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
ATE464303T1 (en) 2004-04-28 2010-04-15 Vertex Pharma COMPOSITIONS SUITABLE AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES
US20100152044A1 (en) * 2004-05-12 2010-06-17 Bayer Cropscience Gmbh Plant growth regulation
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
US8008320B2 (en) 2004-12-08 2011-08-30 Johannes Gutenberg-Universitatis 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
JPWO2006077824A1 (en) * 2005-01-18 2008-08-07 国立大学法人京都大学 Drugs for nerve cell regeneration
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2533241T3 (en) 2005-11-03 2015-04-08 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101443314B (en) 2006-03-13 2014-04-09 杏林制药株式会社 Aminoquinolones as GSK-3 inhibitors
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2125683B1 (en) 2006-12-19 2013-10-23 The Board of Trustees of the University of Illinois 3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
NZ579485A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
AU2008282156B2 (en) 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP5426552B2 (en) 2007-09-11 2014-02-26 杏林製薬株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
MX2010002662A (en) 2007-09-12 2010-04-09 Activx Biosciences Inc Spirocyclic aminoquinolones as gsk-3 inhibitors.
US20110184046A1 (en) 2008-07-11 2011-07-28 Dinah Wen-Yee Sah Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
EP2323622A1 (en) 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
GB201111427D0 (en) * 2011-07-05 2011-08-17 Amakem Nv Novel bisindolylmaleimides, pan-pkc inhibitors
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (en) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituted pyrroles, their use for producing a drug, and the drug on their base
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP0776895B1 (en) * 1995-11-20 1998-10-14 Eli Lilly And Company Protein kinase C inhibitor
EP1019043A4 (en) * 1996-05-07 2003-07-30 Univ Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)

Also Published As

Publication number Publication date
EP1140070A1 (en) 2001-10-10
GB9828640D0 (en) 1999-02-17
WO2000038675A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
AU1877700A (en) Treatment of conditions with a need for the inhibition of gsk-3
AU3180795A (en) Hydrate inhibition
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
AU1772399A (en) Well treatment
AU5038299A (en) Process for the biocidal treatment of surfaces
AU3187595A (en) Compounds for the treatment of restenosis
GB9400538D0 (en) Hydrate inhibition
AU1142600A (en) Catheter
AU7750100A (en) Method for the treatment of obesity
AU2021601A (en) Composition for the treatment of dandruff
AU4369000A (en) Inhibition of complement action
AU3782495A (en) Sewage respiration inhibition
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU3119100A (en) Methods for the prevention and treatment of post-surgical complications
AU6277699A (en) Guarantee 20
AU1940800A (en) Combination therapy for the treatment of sepsis
AU4700197A (en) Corrosion inhibition
AU6508298A (en) Fouling inhibition
AUPP375198A0 (en) An anticorrosion treatment
AU6006099A (en) Preventives or remedies for cachexia
AU1277800A (en) Wood-screw or the like
AU5524399A (en) Inorgasmia treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase